KR870002109A - 디-t-부틸페놀 화합물의 제조 방법 - Google Patents

디-t-부틸페놀 화합물의 제조 방법 Download PDF

Info

Publication number
KR870002109A
KR870002109A KR1019860006534A KR860006534A KR870002109A KR 870002109 A KR870002109 A KR 870002109A KR 1019860006534 A KR1019860006534 A KR 1019860006534A KR 860006534 A KR860006534 A KR 860006534A KR 870002109 A KR870002109 A KR 870002109A
Authority
KR
South Korea
Prior art keywords
compound
formula
hydrogen
bond
produce
Prior art date
Application number
KR1019860006534A
Other languages
English (en)
Other versions
KR870000889B1 (ko
Inventor
앤 패네타 질
Original Assignee
매리 앤 터커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 매리 앤 터커, 일라이 릴리 앤드 캄파니 filed Critical 매리 앤 터커
Publication of KR870002109A publication Critical patent/KR870002109A/ko
Application granted granted Critical
Publication of KR870000889B1 publication Critical patent/KR870000889B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/16—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

디-t-부틸페놀 화합물의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 구조식(A)화합물을 일반식(B)화합물과 반응시켜 R1및 R2가 함께 결합을 나타내고 Q가 NR이며 R3및 R4가 함께 =S를 나타내는 일반식(I)화합물을 생성시키거나 ;
    R3및 R4가 =S를 나타내는 일반식(I)화합물을 환원시켜 R3및 R4가 수소인 일반식(I)화합물을 생성시키거나 ;
    R1및 R2가 결합을 나타내는 일반식(I)화합물을 환원시켜 R1및 R2가 수소인 일반식(I)화합물을 생성시키거나 ;
    R이 수소인 일반식(I)화합물을 알킬화시켜 R이 C1-C4알킬인 일반식(I)화합물을 생성시키거나 ;
    구조식(C)화합물을 포름산과 반응시켜 Q가 산소이고, R1및 R2가 함께 결합을 나타내며, R3및 R4가 수소인 일반식(I)화합물을 생성시키거나, 구조식(C)화합물을 이황화탄소와 반응시켜 Q가 산소이고, R1및 R2가 함께 결합을 나타내며, R3및 R4가 함께 =S를 나타내는 일반식(I)화하불을 생성시킴을 특징으로 하여, 일반식(I)화합물 또는 이의 약학적으로 허용되는 염을 제조하는 방법.
    상기식에서
    Q는 산소 또는 NR (여기서, R은 수소 또는 C1-C4알킬이다)이고 ;
    R1및 R2는 각기 수소이거나, 함께는 결합을 형성하며 ;
    R3및 R4는 각기 수소이거나, 함께는 =S를 나타내고 ;
    단, R1및 R2가 함께 결합을 나타내고, Q가 NH인 경우에 R3및 R4는 단지 수소일 수 있다.
  2. 제1항에 있어서, 하기 일반식(Ⅲ)화합물 또는 약학적으로 허용되는 이의 염을 제조하는 방법.
    상기식에서, R은 수소 또는 C1-C4알킬이다.
  3. 제2항에 있어서, 5-{[3,5-비스(1,1-디메틸에틸)-4-하이드록시페닐]메틸렌}-3-메틸-4-티아졸리딘온을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860006534A 1985-08-09 1986-08-08 디-t-부틸페놀 화합물의 제조 방법 KR870000889B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76416085A 1985-08-09 1985-08-09
US764,160 1985-08-09
US86948886A 1986-06-02 1986-06-02
US869,488 1986-06-02

Publications (2)

Publication Number Publication Date
KR870002109A true KR870002109A (ko) 1987-03-30
KR870000889B1 KR870000889B1 (ko) 1987-05-02

Family

ID=27117408

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860006534A KR870000889B1 (ko) 1985-08-09 1986-08-08 디-t-부틸페놀 화합물의 제조 방법

Country Status (24)

Country Link
EP (1) EP0211670B1 (ko)
JP (1) JPH0625182B2 (ko)
KR (1) KR870000889B1 (ko)
CN (1) CN1014891B (ko)
AR (1) AR243173A1 (ko)
AU (1) AU590312B2 (ko)
CA (1) CA1285572C (ko)
CY (1) CY1619A (ko)
DE (1) DE3670951D1 (ko)
DK (1) DK169324B1 (ko)
ES (1) ES2001075A6 (ko)
GR (1) GR862081B (ko)
HK (1) HK94791A (ko)
HU (1) HU196192B (ko)
IE (1) IE58718B1 (ko)
IL (1) IL79648A (ko)
LV (1) LV10866B (ko)
MX (1) MX9203108A (ko)
MY (1) MY102365A (ko)
NZ (1) NZ217126A (ko)
PH (1) PH24517A (ko)
PT (1) PT83152B (ko)
SG (1) SG80391G (ko)
SU (1) SU1516012A3 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512163D0 (en) * 1985-05-14 1985-06-19 Fujisawa Pharmaceutical Co Oxothiazolidine compound
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US5691367A (en) * 1985-08-09 1997-11-25 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US4897406A (en) * 1987-11-13 1990-01-30 Nisshin Flour Milling Co., Ltd. Rhodanine derivatives and pharmaceutical compositions
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
FI93954C (fi) * 1988-11-29 1995-06-26 Warner Lambert Co Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi
EP0391644B1 (en) * 1989-04-07 1996-06-19 Eli Lilly And Company Aryl-substituted rhodanine derivatives
IL108962A (en) * 1989-12-21 1996-12-05 Lilly Co Eli Use of hydrocarbon-containing sulfur-containing heterocyclic histories, process for their preparation and pharmaceutical preparations containing them
US5216002A (en) * 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
PT97507B (pt) * 1990-04-27 1998-08-31 Orion Yhtymae Oy Processo para apreparacao de novos derivados de catecol farmacologicamente activos
KR0133550B1 (ko) * 1991-01-21 1998-04-23 요시또시 가즈오 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
ES2089736T3 (es) * 1992-10-28 1996-10-01 Shionogi & Co Derivados de bencilideno.
EP0705816B1 (en) * 1993-06-23 2000-09-20 Chugai Seiyaku Kabushiki Kaisha Benzene derivative useful for ischemic diseases
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5476865A (en) * 1994-07-06 1995-12-19 Eli Lilly And Company Methods of inhibiting bone loss
WO1996022772A1 (en) * 1995-01-23 1996-08-01 Eli Lilly And Company Method for treating multiple sclerosis
ES2146837T3 (es) * 1995-09-07 2000-08-16 Lilly Co Eli Procedimiento para preparar derivados de la rodanina sustituidos con bencilo.
WO1998002160A1 (en) * 1996-07-11 1998-01-22 Warner-Lambert Company Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
US6063799A (en) * 1996-09-03 2000-05-16 Eli Lilly And Company Alternate crystal form of Tazofelone
US6005142A (en) 1996-09-03 1999-12-21 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
AU6330999A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
DE202006018406U1 (de) 2006-12-05 2008-04-10 Seda S.P.A. Verpackung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
JPS57130950A (en) * 1981-02-05 1982-08-13 Kanegafuchi Chem Ind Co Ltd 3,5-di-tert-butyl-4-hydroxystyrene derivative and anti- inflammatory, analgesic, antipyretic agent and inhibitor for blood platelet aggregation
JPS5879944A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd ３，５−ジ・タ−シヤリ−・ブチルスチレン誘導体及び抗炎症、鎮痛、解熱剤並びに血小板凝集阻害剤
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds

Also Published As

Publication number Publication date
LV10866A (lv) 1995-10-20
GR862081B (en) 1986-12-24
JPS6242977A (ja) 1987-02-24
NZ217126A (en) 1989-01-27
DK169324B1 (da) 1994-10-10
JPH0625182B2 (ja) 1994-04-06
EP0211670B1 (en) 1990-05-09
MX9203108A (es) 1992-07-01
ES2001075A6 (es) 1988-04-16
CN86105036A (zh) 1987-02-04
HUT42765A (en) 1987-08-28
KR870000889B1 (ko) 1987-05-02
IE58718B1 (en) 1993-11-03
IL79648A (en) 1991-12-12
AR243173A1 (es) 1993-07-30
MY102365A (en) 1992-06-17
PT83152B (pt) 1989-03-30
DK376986A (da) 1987-02-10
EP0211670A2 (en) 1987-02-25
DE3670951D1 (de) 1990-06-13
HK94791A (en) 1991-11-29
CA1285572C (en) 1991-07-02
AU590312B2 (en) 1989-11-02
AU6097286A (en) 1987-02-12
EP0211670A3 (en) 1987-05-06
PT83152A (en) 1986-09-01
HU196192B (en) 1988-10-28
SG80391G (en) 1991-11-15
SU1516012A3 (ru) 1989-10-15
IL79648A0 (en) 1986-11-30
DK376986D0 (da) 1986-08-07
PH24517A (en) 1990-07-18
CN1014891B (zh) 1991-11-27
LV10866B (en) 1996-04-20
CY1619A (en) 1992-07-10

Similar Documents

Publication Publication Date Title
KR870002109A (ko) 디-t-부틸페놀 화합물의 제조 방법
KR840005083A (ko) 항고혈압제로서 유용한 아미노산유도체의 제조방법
KR860001110A (ko) 항균제 ⅱ의 제법
KR870006039A (ko) 신규 티아졸 화합물, 그 제조방법 및 이 화합물을 함유하는 약학적 조성물
KR850005868A (ko) 트리펜디옥사진 비닐 설폰의 제조방법
KR830006906A (ko) 시클로로프로판 카르복실레이트의 제조방법
KR830006198A (ko) 시클로헥산 유도체의 제조방법
KR860001083A (ko) 신규의 모르포리놀의 제법
KR830007655A (ko) 벤조디아제핀 화합물의 제조 방법
KR860008174A (ko) 항정신질환성 벤지소티아졸 s-산화물의 제조방법
ES2001437A6 (es) Procedimiento para preparar complejos de amoniaco de bisditiocarbamatos de zinc
KR830005191A (ko) 푸란유도체의 제조방법
KR870006024A (ko) 니자티딘의 제조방법
KR840007875A (ko) N-(3-트리플루오로메틸페닐)-n'-프로파르길 피페라진의 제조방법
KR840006622A (ko) 1-아로일-5-옥소-2-피롤리딘 프로파논산 및 그의 에스테르의 제조방법
ATE62235T1 (de) Verfahren zur herstellung von 6-amino-3-hydrazino-pyridazinderivaten.
KR910000746A (ko) 1, 1-디옥소페닐실리노일 옥시메틸 d-6-[x-(메틸렌 아미노)페닐-아세트아미도]-페니실라네이트와 그의 파라-톨루엔술폰산염
KR830009044A (ko) 3,5-디-3급부틸-4-하이드록시페닐-치환 복소환 화합물의 제조방법
EP0662475A3 (en) Method for the preparation of 2-perfluoroalkyl-3-oxazolin-5-one
KR860007241A (ko) 2-옥사-또는-아자-프레그난 화합의 제조방법
KR860001790A (ko) 프로카테롤 안정화 방법
KR880005112A (ko) 치환벤조티아졸의 유도체 제조방법
KR870003064A (ko) 아미디노 우레아 유도체의 제조방법
KR840008335A (ko) 살충제의 제조방법
KR890015996A (ko) 1-아미노-2-브로모-4-히드록시 안트라퀴논의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010406

Year of fee payment: 15

LAPS Lapse due to unpaid annual fee